Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
The introduction of elexacaftor/tezacaftor/ivacaftor (ETI), a highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy, to younger ages and the COVID-19 pandemic have significantly reduced pulmonary exacerbations requiring hospitalization among children with CF. To assess demographic and clinical characteristics of children and young adults with CF hospitalized for pulmonary exacerbations before and after pediatric ETI approval.
Leslie Chiang1 , Nanda Ramchandar, Jacquelyn Aramkul, Yaron Fireizen, Mark E. Beatty, Madeleine Monroe, Seema Shah, Jennifer Foley, and Nicole G. Coufal Author affiliation: University of California San Diego, San Diego, California, USA (L. Chiang, N. Ramchandar, Y. Fireizen, J. Foley, N.G. Coufal); Naval Medical Center San Diego, San Diego (N. Ramchandar); Rady Children’s Hospital of San Diego, San Diego (N. Ramchandar, Y. Fireizen, J.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
